Evaluation of the efficacy of monthly oral administration of afoxolaner plus milbemycin oxime (NexGard Spectra®, Merial) in the prevention of adult Spirocerca lupi establishment in experimentally infected dogs  by Beugnet, Frederic et al.
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The  nematode  Spirocerca  lupi  (Rudolphi,  1809)  is widely  distributed  but mostly  occurs  sporadically  with
stable  populations  only  in certain  geographic  areas.  This  helminth  mainly  infects  dogs  and  wild  canids.
Primary  pathology  relates  to migration  of  third  stage  larvae  (L3)  damaging  the  thoracic  aorta  and  estab-
lishment  of adults  in  nodules  in the  oesophagus.  The  objective  of the  present  study  was to  evaluate  the
efﬁcacy  of milbemycin  oxime  in  combination  with  afoxolaner  (NexGard  Spectra®, Merial),  administered
monthly,  in  preventing  establishment  of adult  worms  after  experimental  infection.  Two  groups  consist-
ing of  eight  animals  each  were  experimentally  infected  with  15  L3  on Days  −28,  −14  and  −2, respectively
(45  L3  per  animal  in  total).  Group  1  dogs  served  as  untreated  (negative)  control,  whereas  animals  in  group
2 were  treated  with  NexGard  Spectra® at a minimum  dose  of  0.5  mg/kg  milbemycin  oxime  on  Day  0  and
from  then  onwards  every  28  days  up  to Day  140 (six  treatment  occasions).  Endoscopy  was  performed
on  Day 112  and  for some  animals  also  Day  140.  Necropsy  for worm  recovery  and  nodule/lesion  scoring
was  performed  on  Day  168. All  eight  animals  in  the  control  group  (group  1)  presented  with  1–3 nodules
and  worm  counts  ranging  from  9  to  41.  Six  animals  in the  NexGard  Spectra® group  presented  with  1–4
nodules  and worm  counts  ranging  from  1 to 5.  Signiﬁcantly  (p  <  0.05)  fewer  worms  were  collected  from
treated  animals  in  the treated  group  (geometric  mean  1.7)  versus  the  negative  control  group  (geometric
mean  22.0)  with  92.3%  efﬁcacy  calculated.  There  was no  signiﬁcant  (p  >  0.05)  difference  between  groups
with  reference  to number  of nodules  in the  oesophagus.  However,  nodules  in the  control  group  were
signiﬁcantly  (p <  0.05)  larger  than  those  in the  treated  group.Number  and  size  of  lesions  in  the  dorsal  aorta  did  not  differ  statistically  between  groups  1 and  2.
Because  NexGard  Spectra® was  administered  28  days  after  onset  of inoculation,  migrating  and  developing
L3 caused  damage  to  the  aorta  wall  of  animals  in  the  treated  group.  Milbemycin  oxime  (administered  as
NexGard  Spectra®) demonstrated  effectiveness  in  reducing  infection  with  adult  Spirocerca  lupi  worms  in
the oesophagus.
© 2016  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. IntroductionSpirocerca lupi (Rudolphi, 1809), a nematode (Harmelin et al.,
991; Minnaar et al., 2002; Oliveira-Sequeira et al., 2002; Thevenet
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itas, 9321, Bloemfontein, South Africa.
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D. Crafford).
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304-4017/© 2016 The Authors. Published by Elsevier B.V. This is an open access article 
/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
et al., 2004) of the family Spirocercidae, mainly infects dogs and
wild canids but may also infect other carnivores (Bailey, 1963;
Segovia et al., 2001). It appears to be most prevalent in tropical
and subtropical regions (van der Merwe et al., 2008). The distribu-
tion is worldwide but S. lupi prevalence is highly variable, stable in
certain well-deﬁned geographic areas and sporadic in various other
regions. Monthly or seasonal distribution of the disease (spirocer-
cosis) is not always evident (Lobetti, 2000, 2014), but prevalence
may  be higher during colder months (Mazaki-Tovi et al., 2002).
Some studies implicate no preference for age (Lobetti, 2000, 2014),
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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ut Mazaki-Tovi et al. (2002) found that dogs aged 12 months and
ounger appear to be at greater risk. Kok et al. (2010) found an 88.9%
revalence of S. lupi in six month old pups raised in an endemic area
n South Africa, where 24 out of 27 animals in the negative control
roup became naturally infected.
There also appears to be no preference for any speciﬁc breed or
ex, but large breeds are considered to be at greater risk of infection
Lobetti, 2000, 2012; Mazaki-Tovi et al., 2002; van der Merwe et al.,
008). The disease appears to have a primarily urban pattern of
istribution (Mazaki-Tovi et al., 2002). Proximity to paratenic and
ntermediate hosts, as well as the population density of such hosts,
re the most important factors affecting prevalence (van der Merwe
t al., 2008). Paratenic hosts may  include lizards (Anantaraman and
en, 1966), rabbits (Chowdhury and Pande, 1969), poultry, wild
irds, rodents and hedgehogs (van der Merwe et al., 2008). Because
f this van der Merwe et al. (2008) warn that prevalence data can be
isleading and must be interpreted with reference to the dog popu-
ation sampled. Factors to be considered include status (stray versus
omestic pet), region of the country sampled, environment (urban
ersus rural) and the method of diagnosis or evaluation (necropsy
r endoscopy versus faecal ﬂotation). Changes in any of these fac-
ors can also result in changes in prevalence data over time in a
peciﬁc region.
Knowledge on the life cycle of a parasite is paramount for a num-
er of reasons. Firstly, it allows understanding of pathology and
otential impact on host health, but it is also critical for devel-
pment of effective control strategies and experimental models
hrough which to evaluate the efﬁcacy of veterinary products. The
ife cycle of S. lupi proceeds as follows: Coprophagous beetles act-
ng as intermediate hosts (Chhabra and Singh, 1973; Du Toit et al.,
012, 2008) ingest S. lupi eggs. First stage larvae (L1) are present in
eetles from around 36 h (Chhabra and Singh, 1972) and develop
o infective third stage larvae (L3) within eight days (Chhabra and
ingh, 1977) to two months (van der Merwe  et al., 2008), depend-
ng on temperature. The infective L3 may  also excyst and re-encyst
ithin the tissues of a variety of paratenic hosts. When either
he intermediate or paratenic host is ingested by the ﬁnal host,
he L3 penetrates the gastric mucosa within 2 h and reaches the
erosal surface within 24–48 h (van der Merwe et al., 2008). Migrat-
ng through gastric arteries and later the coeliac artery, L3 stages
each the caudal thoracic aorta approximately 10 days after being
ngested (van der Merwe  et al., 2008) (denoted in the format “Day
0” with reference to discussions to follow). Here they remain up
o approximately Day 109 and develop into L4 and ﬁnally imma-
ure adults (Anantaraman and Sen, 1966; van der Merwe et al.,
008) before migrating to the oesophagus. Adults may  already be
resent in the oesophagus from as early as Day 93 (van der Merwe
t al., 2008). Oesophageal nodules containing worms could thus be
resent by three to eight months (93–227 days) after infection (van
er Merwe et al., 2008). A diagrammatic representation of the key
evelopment periods is provided as Fig. 1.
Considering the life cycle and available literature, pathology in
he ﬁnal host is predominantly related to either 1) migration of lar-
ae or immature adults, most notably through the thoracic aorta
o reach the oesophagus, and 2) development of nodules in the
esophagus when adult worms establish there. Migration of larvae
nd development to L4 and immature adults in the wall of the cau-
al thoracic aorta may  weaken the aorta wall, result in aneurysms
Kirberger and Zambelli, 2007) and even sudden death due to aortic
upture (Kirberger et al., 2013a,b). Also associated with this migra-
ion event is the possibility of larvae ending up in tissues other than
he oesophagus, most notably the spine, resulting in partial or com-
lete pelvic limb lameness (Tudury et al., 1995; Chai et al., 2008;
indsay et al., 2010). Apart from aberrant larval migration and sec-
ndary inﬂammation caused by aortic migration, caudal thoracic
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factors, related to the adult worm or oesophageal lesion, may  also
play a signiﬁcant role (Kirberger et al., 2013a,b). Formation of nod-
ules in the oesophagus (Avner and Herrtage, 2013; Sasani et al.,
2014), or more rarely in the stomach (Sasani et al., 2014; Giannelli
et al., 2014), may  lead to physical obstruction making swallowing
difﬁcult and resulting in abnormal clinical signs such as dyspnoea
and regurgitation (Giannelli et al., 2014). In some cases such nodu-
lar growths can be surgically removed (Ranen et al., 2004; Giannelli
et al., 2014) or managed by other means such as transendoscopic
neodymium:yttrium-aluminum-garnet laser ablation and polypec-
tomy snare electrocautery (Yas et al., 2013). These inﬂammatory
ﬁbroblastic nodules may  progress to a sarcoma in approximately
25% of cases (Dvir et al., 2011) through malignant neoplastic trans-
formation (Dvir et al., 2008; Dvir et al., 2010; Mukorera et al., 2011;
Rosa et al., 2013). Such growths are often fatal (da Fonseca et al.,
2012) and in severe cases may result in extraskeletal osteosarcoma
metastasis to the brain and spinal cord (Pazzi et al., 2013). In addi-
tion material leaking from the oesophagus into the pleural cavity
may  result in pyothorax (Klainbart et al., 2007).
Because of the severe health risk the nematode poses to com-
panion animal health, effective control is required. Therapeutic
measures may  be aimed either at preventing migration and estab-
lishment of L3 in the dorsal aorta, preventing establishment of adult
worms in the oesophagus, or both.
Natural infection efﬁcacy study design allows for two
approaches: protection against naturally acquired infections (Kok
et al., 2010; Le Sueur et al., 2010) and treatment of existing infec-
tions (Berry, 2000; Kelly et al., 2008; Lobetti, 2012; Okanishi et al.,
2013; Sheta et al., 2014). For experimental studies more ﬂexi-
ble designs are possible, with treatments potentially commencing
prior to infection (prophylactic effect) (Lavy et al., 2003), prior to
establishment of the adults (Kok et al., 2011) or after adults have
established (Lavy et al., 2002). Depending on the number of groups
included in the study, design can be adapted to evaluate efﬁcacy
against both immature (prophylactic) and adult stages (Austin et al.,
2013).
Active ingredients for which studies against S. lupi have been
published include doramectin (Berry, 2000; Lavy et al., 2003, 2002;
Lobetti, 2012), milbemycin oxime (Kelly et al., 2008; Kok et al.,
2010; Kok et al., 2011; Okanishi et al., 2013), imidacloprid plus mox-
idectin combinations (Le Sueur et al., 2010; Austin et al., 2013) and
ivermectin combined with prednisolone (Sheta et al., 2014).
The objective of this study was  to evaluate the efﬁcacy of milbe-
mycin oxime in combination with afoxolaner (NexGard Spectra®,
Merial), administered monthly, against the establishment of adult
worms in the oesophagus after experimental infections with third
stage S. lupi larvae. Milbemycin oxime is known to be effective
against S. lupi (Kok et al., 2010; Kok et al., 2011) and hence efﬁ-
cacy of this active ingredient in combination with afoxolaner will
be evaluated. Afoxolaner is known to be effective against ﬂeas and
ticks (Beugnet et al., 2015).
2. Materials and methods
2.1. Study layout and design
This parallel group, blinded, controlled efﬁcacy study was con-
ducted on two groups containing eight mixed breed dogs each. The
study was  conducted in three phases because of the seasonal vari-
ation in abundance of intermediate hosts and parasite prevalence.
Phases consisted of six, six and four animals, respectively. All three
phases were conducted under the same conditions employing the
same methodology. For statistical analyses data were pooled. For
ease of discussion the pooled data will be reported on and distinc-
tion will not be made between phases. Acclimatisation commenced
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wFig. 1. Diagrammatic summary of key Spirocerca lupi development periods [compi
n Day-35 with experimental infection commencing on Day-28.
reatment with Nexgard Spectra® was performed on Day 0 with
nimal phase study termination on Day 168. Ethics approval was
ranted by the Clinvet Committee for Animal Ethics and Welfare
CCAEW), in accordance with the South African National Stan-
ard on the care and use of animals for scientiﬁc purposes (SANS
0386:2008–Edition 1) Annex F, F.1.2, prior to conduct of the study.
peciﬁc conditions approved were the use of purpose bred animals,
ndividual housing and animal restraint for short periods for study
rocedure purposes.
.2. Study preparation and animal details (sex and weight
riteria)
Purpose bred dogs were treated with a short-acting
nthelmintic 20 days prior to the start of acclimatisation and
ad no resident helminth infections when they were enrolled in
he study. Group 1 was a negative control group and consisted of
hree males and ﬁve females. Animals in group 2 were treated with
foxolaner and milbemycin oxime (NexGard Spectra®, Merial)
nd consisted of four males and four females. Weight was  used as
anking criterion during group allocation. The weight range prior
o initial experimental infection was 9.80 kg–14.95 kg (arithmetic
ean 13.26 kg) and 11.83 kg–15.62 kg (arithmetic mean 13.52 kg)
or groups 1 and 2, respectively, as measured on Day-29. The
roups were homogenous at time of inclusion with no signiﬁcant
p > 0.05) difference in weight between groups. In addition the dogs
ere weighed monthly on Days -1, 27, 55, 83, 111, 139 and 167
±3 days deviation allowed between phases, with the exception of
ay-1) to allow comparison of weight gain/loss between groups
ver the study period.
.3. Housing and feeding
The dogs were individually housed inside a brick and steel
utdoor housing unit subject to ambient environmental condi-
ions. The ﬂoor size of each dog cage was 3.0 m × 1.5 m and dogs
ere protected against rain. The accommodation was  assigned
ith consideration of the South African National Standard, SANSing information from Anantaraman and Sen (1966); van der Merwe  et al. (2008)].
10386:2008 “The care and use of animals for scientiﬁc purposes”.
Water was available ad libitum in concrete troughs ﬁtted with a
ball-valve system. The animals were fed once a day according to
the commercial food manufacturer’s recommendation, with the
exception of the following special feeding instructions as per study
design: dogs were fasted approximately 12 h prior to every experi-
mental infection; dogs were fasted at least 12 h prior to endoscopy
for the purposes of sedation and endoscopy; dogs were fasted
16–20 h prior to necropsy.
2.4. Experimental infection with Spirocerca lupi
Infective L3 larvae of S. lupi were dissected from naturally
infected scarabaeid beetles collected in the Eastern Cape, South
Africa, in an area endemic for spirocercosis.
The beetles are often infected with other smaller nematodes,
but the S. lupi larvae can easily be distinguished by their larger
size and typical shape of the tail (Chhabra and Singh, 1972). The
excysted larvae were kept in saline and used within 24 h of their
recovery. Animals in both groups were infected with 15 S. lupi lar-
vae (suspended in 1–2 mL  of saline solution) on Days -28, -14 and -2,
respectively. Dogs were fasted for approximately 12 h before each
experimental infection. Acepromazine Maleate was administered
to dogs at the registered dose (0.05 mL/kg im)  to suppress vomiting,
after which the S. lupi larvae were dosed directly into the stomach
with the aid of a stomach tube, rinsed through with approximately
5–10 mL  of saline solution.
2.5. Treatment with NexGard Spectra®
NexGard Spectra® was  administered to the eight dogs in group
2 on Days 0, 28, 56, 84, 112 and 140, respectively. The dosage was
adapted in order to be as close as possible to the minimum dose
of 0.5 mg  milbemycin oxime per kilogram body weight (0.5 mg/kg)
using commercial presentation. The actual dose in mg/kg admin-
istered to dogs in group 2 on the respective treatment occasions
ranged between 0.50 mg/kg and 0.97 mg/kg (Table 1). The change
in dosage was  seen in dogs weighting above 15 kg due to a change
in chew size. Chews were administered directly into the mouth,
F. Beugnet et al. / Veterinary Parasitology 226 (2016) 150–161 153
Table  1
Milbemycin doses administered to dogs.
ID Date Body weight (kg) Milbemycine dose rate
(mg/kg)
5C2 9F1 29-May-15 12.32 0.61
26-Jun-15 11.88 0.63
24-Jul-15 12.01 0.62
21-Aug-15 11.97 0.62
18-Sep-15 12.00 0.62
16-Oct-15 12.80 0.58
5C3 AEC 20-Apr-15 14.95 0.50
18-May-15 15.90 0.94
15-Jun-15 16.01 0.93
13-Jul-15 18.47 0.81
10-Aug-15 20.45 0.73
07-Sep-15 19.40 0.77
5C4 87C 08-May-15 13.60 0.55
05-Jun-15 14.25 0.52
03-Jul-15 15.29 0.98
31-Jul-15 14.54 0.51
28-Aug-15 14.15 0.53
25-Sep-15 14.51 0.52
5C6 CF6 08-May-15 12.18 0.61
05-Jun-15 12.62 0.59
03-Jul-15 12.95 0.58
31-Jul-15 13.13 0.57
28-Aug-15 12.96 0.57
25-Sep-15 13.30 0.56
5C9 139 29-May-15 12.78 0.58
26-Jun-15 12.88 0.58
24-Jul-15 12.86 0.58
21-Aug-15 12.25 0.61
18-Sep-15 12.20 0.61
16-Oct-15 12.82 0.58
5D5 A03 20-Apr-15 13.85 0.54
18-May-15 14.16 0.53
15-Jun-15 13.71 0.54
13-Jul-15 13.71 0.54
10-Aug-15 15.35 0.97
07-Sep-15 14.92 0.50
5D7 378 08-May-15 13.44 0.56
05-Jun-15 13.43 0.56
03-Jul-15 14.06 0.53
31-Jul-15 13.28 0.56
28-Aug-15 12.80 0.58
25-Sep-15 13.58 0.55
5E0 749 20-Apr-15 15.93 0.94
18-May-15 15.35 0.97
15-Jun-15 14.00 0.53
13-Jul-15 14.96 0.50
p
m
t
t
o
c
a
a
2
D
t
-
p
d
0
w10-Aug-15 16.75 0.89
07-Sep-15 15.84 0.94
laced in the back of the throat past the base of the tongue. The
outh cavity was checked following administration of the tablets
o ensure that ingestion had occurred. Care was taken to ensure
hat all animals received the full amount of the dose without loss
f product. None of the dogs regurgitated, vomited or spat out the
hew treatment.
A tabulated summary showing days of experimental infection
nd administration of NexGard Spectra® in relation to the key par-
site development periods, is provided in Table 2.
.6. Observations
A veterinarian conducted a clinical examination on all dogs on
ay −35 for enrolment and on Day -29 for inclusion purposes. Addi-
ionally, clinical examinations were performed monthly on Days
1, 27, 55, 83, 111, 139 and 167 (±3 day deviation allowed between
hases with the exception of Day -1). All the dogs were observed
aily from Day -35 to Day 168 for general health and from Days
–168 for clinical signs of adverse reactions following treatment
ith NexGard Spectra®. The dogs were also observed hourly forFig. 2. Spirocerca lupi eggs showing the characteristic shape with larva visible inside
the  egg.
four hours after infection with S.lupi, for signs of vomiting, which
was recorded. In addition dogs were observed for possible adverse
reactions hourly for four hours after treatment of the last animal
with NexGard Spectra®.
2.7. Endoscopic examination
Dogs in all groups were scheduled to be endoscopically exam-
ined on Days 112 and 140, but logistical constraints (technical
difﬁculties with endoscope) resulted in delays in phases 1 and
3, which led to some animals not being examined on Day 140.
General anaesthesia was  required for the endoscopy procedure.
Each patient received 0.5 mL/10 kg diazepam iv and 0.2 mg/10 kg
atropine iv 10 min  prior to induction of anaesthesia. If considered
necessary to inhibit excessive gastrointestinal secretions, the dose
was sequentially increased. The patient was induced with propofol
iv to effect, intubated and the cuff inﬂated. The patient was  main-
tained on halothane inhalation anaesthesia in lateral recumbency
with the head and neck extended.
The endoscope tip was  lubricated and carefully directed into
the oesophagus, which was  insufﬂated with air until the lumen
could be clearly visualized before advancing the endoscope. The
oesophageal mucosa was  examined over its whole length up to the
gastroesophageal oriﬁce.
2.8. Faecal egg counts
Faecal S. lupi egg counts were conducted on Days 112, 140 and
168 (deviation of ±3 days allowed between phases). Faeces were
collected from each dog’s cage. A centrifugation method employing
a saturated sugar solution (adopted from Markovics and Medinski,
1996) was  used and the egg counts expressed as Eggs Per Gram of
faeces (EPG). Examples of S. lupi eggs are provided in Fig. 2.
2.9. Necropsy
Necropsy of all animals were performed on Day 168. At
necropsy, an extensive post-mortem examination of the thoracic
aorta and oesophagus was  conducted and all lesions described and
quantiﬁed. The number of nodules (oesophagus) or lesions (tho-
racic aorta) were recorded and the diameter of such nodules/lesions
were measured. Photographic documentation was also compiled.
All nodules were opened and the contents washed through a
0.15 mm sieve. After backwashing, the contents of the sieve were
preserved in 10% formalin. All worms collected at necropsy were
identiﬁed within sex and counted. Presence in oesophageal nodules
in the oesophagus is characteristic for Spirocerca spp. and species
identiﬁcation was  conﬁrmed based on Segovia et al. (2001). Para-
sites were ﬁxed in 10% formalin.
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Table 2
Inoculation and NexGard Spectra® treatment occasions related to anticipated parasite location and developmental stage involved. based on Spirocerca lupi life cycle (see
Fig. 1).
Study day IVP Worm stage and anticipated location based on life cycle during each of the three inoculation occasions
INOC 1 INOC 2 INOC 3
−28 No L3/stomach – –
−14 No  L3 aorta L3/stomach –
−2  No L4 aorta L3 aorta L3/stomach
0  Yes L4 aorta L4 aorta L3/stomach
28  Yes L4 aorta L4 aorta L4 aorta
56  Yes L4 aorta L4 aorta L4 aorta
84  Yes Imm  adult esoph Imm  adult esoph L4 aorta
112  Yes Patent adult esoph Imm adult esoph Imm adult esoph
140  Yes Patent adult esoph Patent adult esoph Imm adult esoph
168  No Patent adult esoph Patent adult esoph Patent adult esoph
IVP = Investigational Veterinary Product administered?.
INOC = Inoculation occasion (experimental infection with 15 Spirocerca lupi larvae).
L3  = Third stage larvae.
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e4 = Fourth stage larvae.
mm  = Immature.
soph = Oesophagus.
.10. Efﬁcacy criteria
The primary numerical variable for statistical analysis was the
ount of worms recovered at necropsy. Percentage efﬁcacy, as a
easure of a treatment effect to prevent nodule formation and the
stablishment of adult worms, was the primary endpoint for the
tudy. Adequacy of infection and a signiﬁcant difference in worm
ounts between the NexGard Spectra® and control groups were
equired to claim a preventive effect of treatment.
Secondly, the NexGard Spectra® group was also statistically
ompared to the control group with regard to the reduction in faecal
gg output as determined on Days 112, 140 and 168. The percent-
ge faecal egg count reduction, as a measure of a NexGard Spectra®
reatment effect, was a secondary endpoint.
Lastly, the nodules and damage to the aorta and oesophagus
ere described and discussed.
.11. Statistical analyses
VICH guidelines (GL 19) (Veterinary International Cooperation
n Harmonization, 2001) specify six adequately infected animals
er group as the requirement for efﬁcacy studies. Eight animals
ere used per group to ensure that the requirement could be met.
The statistical unit was the individual animal when individual
bservations were made. The statistical unit was the group if central
alues of a group were compared. The level of signiﬁcance of the
ormal tests was set at 5%, all tests were two-sided.
.11.1. Comparison of body weight
The body weight was compared between the groups using a one-
ay ANOVA (Proc GLM procedure in SAS) with a treatment effect
n the original body weights, assuming a normal distribution of the
ata. Weight gain/loss over the study period was also compared
etween groups as an additional safety parameter. The two groups
ere compared with respect to the change from baseline (Day -
9) in body weight on each weighing day by an ANOVA with a
reatment effect.
.11.2. Endoscopic examination
Data on the presence and numbers of visible nodules in theesophagus were tabulated descriptively. Endoscopy were only
erformed to verify success of experimental infection in the control
roup, but only results from necropsy examinations were used to
valuate the set objectives of the study.2.11.3. Percentage egg reduction based on faecal egg counts
The efﬁcacy of administration with NexGard Spectra® to reduce
faecal egg (EPG) output in dogs in the treated group compared
to those in the control group were expressed as percentage egg
reduction, calculated for each faecal egg count (FEC) occasion. The
formula was:
%Eggreduction = (E1 − E2)/E1 × 100
where E1 = Mean egg count for group 1(control)
E2 = Meaneggcountforgroup2(NexGardSpectra®)
with Mean = Geometric mean (Geo mean) considered primary
To allow for data sets with zero values, all data were trans-
formed to (count + 1), Geo means calculated and 1 subtracted from
the result to obtain a reasonable estimate of the Geo  mean.
2.11.4. Efﬁcacy to prevent establishment of Spirocerca lupi adults
The efﬁcacy of administration with NexGard Spectra® to prevent
establishment of S. lupi adults was reﬂected in the number of S. lupi
worms recovered at necropsy in the treated group compared to the
negative control group.
The formula was:
%Efﬁcacy = (N1 − N2)/N1 × 100
where N1 = Mean number of S. lupi recovered at necropsy for group
1 (control)
N2 = Mean number of S. lupi recovered at necropsy for group 2 (NexGard Spectra®)
with Mean = Geo mean considered primary as per VICH GL19
(Veterinary International Cooperation on Harmonization, 2001).
For calculations of efﬁcacy, Geo means were used and calculated
as described in Section 2.11.3 above.
2.11.5. Comparison between groups (faecal egg counts and worm
counts)
For comparison between groups, an Analysis of Variance
(ANOVA) with a treatment effect was applied to the numbers of
worms and EPG counts after a logarithmic transformation of the
“count + 1” data.
In addition, the groups were compared using an ANOVA with
treatment effect on untransformed worm count data. SAS Version
9.3 (TS Level 1M2) was used for all the statistical analyses.
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Table  3
Details on the number of nodules recorded during endoscopy examination and at necropsy.
Group Animal ID Number of nodules found during endoscopy examination on:Number of nodules found during necropsy on:
Day 112 Day 140 Day 168
Group 1 Negative Control 57B 8C7 2 2 2
5B0 FF8 2 3 2
5D0 4D0 2 2 1
5C7 82D 2 NA 3
5CE 5EF 3 NA 3
5D0 C34 5 NA 1
5B1 C83 2 2 2
5B8 A7F 3 2 2
Group 2 NexGard Spectra® 5C3 AEC 2 2 0
5D5 A03 1 3 4
5E0 749 5 4 0
5C4 87C 2 NA 1
5C6 CF6 2 NA 2
5D7 378 2 NA 2
5C2 9F1 2 2 3
5C9 139 1 1 
NA = Not applicable (endoscopy could not be performed due to instrument malfunction).
Table 4
“Percentage egg reduction calculated using geometric means for Spirocerca lupi egg
counts.
Day Geometric mean Percentage efﬁcacy p-value
Group 1 Group 2
Day 112 0.0 0.0 Not applicable Not applicable
Day 140 3.5 0.0 100.0% 0.0003
Day 168 12.7 0.0 100.0% <0.0001
p-value: One-way ANOVA with a treatment effect.
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.11.6. Post-mortem examination
Data on the frequency and size (largest and total) of nod-
les/lesions in the thoracic aorta and oesophagus (each variable
eparately) were calculated per animal, and summarised descrip-
ively for the two groups.
Non-parametric group comparisons were performed on total
umber of nodules/lesions for both aorta and oesophagus (each
ariable separately) using a Mann-Whitney Test. The groups were
lso compared with respect to the mean total size of the nod-
les/lesions using an ANOVA with a treatment effect. Total size
as calculated as follows: Summation of length and width mea-
urement of each individual nodule/lesion gave the total size for
hat nodule/lesion. Summation of total size of all nodules/lesions
er animal provided the total size for that animal.
. Results
.1. Body weight
No signiﬁcant differences (p > 0.05) in weight gain or loss were
bserved between the negative control group and the NexGard
pectra® treated group on any of the assessment days.
.2. Observations and concomitant medication
Some animals in both groups 1 and 2 appeared “thin” and
listless” during clinical examinations, which could potentially be
elated to Spirocerca sp. infection, but more likely to young age and
igh activity level.
They received a high quality food, which was continuously
dapted to their growth rate and their body weights were contin-
ously increasing.4
Abnormal clinical signs observed during daily health observa-
tions included blood in loose faeces and a small wound adjacent to
the eye. Neither of these were considered to be related to treatment
with NexGard Spectra®. Concomitant therapy provided included a
prescription diet and treatment of conjunctivitis with a registered
product.
Four dogs in both groups 1 (control) and 2 (NexGard Spectra®)
vomited at least once after inoculation (Days -28, -14 and -2), but
in the majority of cases vomit was  again consumed within three
hours. No additional inoculations were performed.
No abnormal signs were observed during speciﬁc post-
administration observations, performed after administration of
NexGard Spectra®.
3.3. Endoscopic examination
On Day 112 oesophageal nodules were present in all animals
(both groups, Table 3). On Day 140 nodules were still recorded as
present in all of the Phase 1 and Phase 3 dogs (control and treated).
Endoscopy for dogs in Phase 2 could not be performed on Day 140
due to malfunction of the endoscope. Nodules were found in six
of the eight dogs in treated group and all control dogs at necropsy
(Table 3).
3.4. Faecal egg counts and faecal egg count percentage reduction
On Day 112 no eggs were present from any dogs but eggs were
present on Days 140 and 168. Eggs were present in faecal specimens
from 7 out of 8 untreated control animals on Day 140 (range 1–12)
and in faecal specimens of all 8 untreated control animals on Day
168 (range 2–60).
No eggs were present in faecal specimens from treated dogs
on any of the assessment days, resulting in a signiﬁcant difference
between control and treated groups on both Days 140 and 168.
As a result NexGard Spectra® was  100% effective in reducing the
number of eggs produced by S. lupi on these days (Table 4).
3.5. Lesion evaluation during post mortem examination
3.5.1. Aorta
3.5.1.1. Number of lesions. In the negative control group 1 the nod-
ules/lesions on the inside of the thoracic aorta varied from 4 to 12
in number among individual dogs (Table 5). Typical nodules were
mostly absent and the lesions remaining were usually puckered
areas and small to large aneurisms. No S. lupi worms remained in
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Table 5
Total number of Spirocerca lupi lesions in the oesophagus and aorta per group and comparison between groups.
Location Number of nodules/lesions Group 1 (negative control) Group 2 (NexGard Spectra®) p-value
n/N % n/N %
Oesophagus 1 2/8 25.0% 1/8 12.5% 0.3083
2  4/8 50.0% 2/8 25.0%
3  2/8 25.0% 1/8 12.5%
4  0/8 0.0% 2/8 25.0%
Thoracic aorta 1 0/8 0.0% 1/8 12.5% 0.3652
4  1/8 12.5% 1/8 12.5%
5  1/8 12.5% 3/8 37.5%
8  2/8 25.0% 1/8 12.5%
9  1/8 12.5% 0/8 0.0%
10  1/8 12.5% 0/8 0.0%
12  2/8 25.0% 1/8 12.5%
18  0/8 0.0% 1/8 12.5%
n = number of positive cases; N = number of dogs in group; % = percentage of dogs.
Table 6
Number of Spirocerca lupi worms recovered at necropsy on Day 168.
Group Phase Animal ID S. lupi worms  recovered
Male Female Larvae Total
1 Phase 1 57B 8C7 8 19 0 27
5B0  FF8 12 22 0 34
5D0  4D0 6 10 0 16
5C7  82D 4 5 0 9
Phase 2 5CE 5EF 7 19 0 26
5D0  C34 8 10 0 18
Phase 3 5B1 C83 19 22 0 41
5B8  A7F 11 10 0 21
Geometric means 8.58 13.24 0.00 22.02
Arithmetic means 9.38 14.63 0.00 24.00
2  Phase 1 5C3 AEC 0 0 0 0
5D5  A03 2 1 0 3
5E0  749 0 0 0 0
5C4  87C 1 3 0 4
Phase 2 5C6 CF6 0 1 0 1
5D7  378 1 4 0 5
Phase 3 5C2 9F1 1 1 0 2
5C9  139 0 3 0 3
Geometric means 0.49 1.24 0.00 1.71
Arithmetic means 0.63 1.63 0.00 2.25
Group 1: Negative control.
Group 2: Dogs received the IVP NexGard Spectra® orally.
Fig. 3. Photographs showing typical lesions in the dorsal aorta from both untreated
(negative control group) and treated (NexGard Spectra® group) dogs.
Negative control dogs (group 1): Codes I, K and M.
Treated dogs (NexGard Spectra® , group 2): Codes G, H and O.
Considering all assessments (phases 1–3 combined), there was  no statistical differ-
ence in aorta lesion number, size or severity score between groups. However, lesions
in  the negative control group generally did present with deeper pits and aneurysms
visible.
Table 7
Efﬁcacy using geometric and arithmetic means for Spirocerca lupi worm counts.
Day Mean Mean Efﬁcacy (%) p-value
Group 1 Group 2
Day 168 Geometric 22.02 1.71 92.3 <0.001
Arithmetic 24.00 2.25 90.6 <0.001
p-value: One-way ANOVA with a treatment effect.
Group 1: Negative control.
Group 2: Dogs received the IVP NexGard Spectra® orally.
the wall of the aorta. In NexGard Spectra® group the lesions on the
inside of the thoracic aorta varied from 1 to 18 in number among
individual dogs. There was no statistically signiﬁcant difference
(p > 0.05) in the number of nodules observed in the aorta in the
Nexgard Spectra® treated group compared to the negative control
group.
3.5.1.2. Size of lesions. For negative control group the size of the
nodules/lesions in the thoracic aorta ranged from 272 mm2 to
1150 mm2. In comparison, for animals in NexGard Spectra® group,
the size of the nodules/lesions in the thoracic aorta ranged from
25 mm2 to 748 mm2 (Table 8, Fig. 3). No signiﬁcant differences
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Table  8
Total size (mm2) of Spirocerca lupi lesions in the oesophagus and aorta per group
and  comparison between groups.
Location Statistic Group 1 (mm2) Group 2 (mm2) p-value
Oesophagus n 8 6 0.0108
Mean 1165.6 494.8
SD 493.59 258.19
CV% 42.35 52.18
GeoMean 1058.6 437.6
Median 1115.0 439.5
Minimum 372 192
Maximum 2030 883
Thoracic aorta n 8 8 0.6631
Mean 511.5 456.0
SD 275.77 219.89
CV% 53.91 48.22
GeoMean 465.8 345.7
Median 423.0 461.0
Minimum 272 25
Maximum 1150 748
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etween the NexGard Spectra® treated group and negative control
roup were observed for lesions in the thoracic aorta.
.5.2. Oesophagus
.5.2.1. Number of nodules. In the negative control group, nodules
ere present in the oesophagus of all dogs and ranged from 1
o 3 in number. In the NexGard Spectra® treated group, nodules
ere present in the oesophagus of 6 of the 8 dogs, ranging from
 to 4 in number. There was no statistically signiﬁcant difference
p > 0.05) in the number of nodules observed in the oesophagus
n the NexGard Spectra® treated group compared to the negative
ontrol group.
.5.2.2. Size of nodules. For negative control group the size of the
odules in the oesophagus ranged from 372 mm2 to 2030 mm2
Table 8, Fig. 4). In comparison, for animals in NexGard Spectra®
roup, the size of the nodules in the oesophagus ranged from
92 mm2 to 883 mm2 (Table 8, Fig. 5). Signiﬁcant (p < 0.05) differ-
nces between the NexGard Spectra® treated group and negative
ontrolled group were observed for nodule size, with nodules size
eing greater for the negative control group.
.6. Necropsy worm counts and preventative efﬁcacy against
stablishment of adult stages
In the negative control group, S. lupi worms were recovered
rom all eight of the dogs at necropsy on Day 168. Numbers ranged
etween 9 and 41 (Geo Mean 22.02, Tables 6 and 7).
In the NexGard Spectra® treated group, S. lupi worms were also
ecovered from all eight of the dogs at necropsy on Day 168. Num-
ers ranged between 1 and 5 (Geo Mean 1.71, Tables 6 and 7).
The control and the treatment group differed signiﬁcantly
p < 0.05) with regard to the number of worms recovered at
ecropsy based on both Geo Mean and Arithmetic Mean values.
Efﬁcacy of treatment with the orally administered anthelmintic
ormulation, NexGard Spectra® tablets, was 92.3% effective in the
revention of the establishment of adult S. lupi infections in exper-
mentally infected dogs given 7 consecutive monthly treatments
Table 7).
. DiscussionWeight loss may  be a clinical sign of S. lupi infection (Harmelin
t al., 1991; Lobetti, 2000; Mazaki-Tovi et al., 2002; Last and Smith,
007; van der Merwe et al., 2008), but both groups presented withitology 226 (2016) 150–161 157
weight gain over the study period with no signiﬁcant difference
(p > 0.05) between groups. Mazaki-Tovi et al. (2002) considered
weight loss to be the result of a caudal oesophageal mass, resulting
in difﬁculty to swallow as well as regurgitation of food. The nodules
present during the current study were not large enough to similarly
inﬂuence body weight, a conclusion also made by Lavy et al. (2002).
Weight loss may  be expected to occur only during more advanced
stages of spirocercosis or over a longer period. The dogs included
in the study were also young and still in growth.
Approximately half of the animals vomited after experimen-
tal infection, despite receiving acepromazine to prevent vomiting.
Kok et al. (2011) reported the same outcome but stated that this
had no signiﬁcant effect on establishment of infection, with mean
establishment rates in the control group calculated as 43.3%.
In the current study, considering that in total 45 L3 were admin-
istered per animal, establishment rates in the control group ranged
from 20.0% to 91.1% (arithmetic mean 53.3%). It can be concluded
that vomiting after experimental infection also did not have any
negative effect on establishment of infection in the current study.
The use of oesophagoscopy to detect oesophageal nodules asso-
ciated with S. lupi infections is a standard diagnostic procedure
(Mazaki-Tovi et al., 2002) and has been used often in studies to
determine the efﬁcacy of therapeutic procedures in the treatment
of progressed spirocercosis (Berry, 2000; Lavy et al., 2003; Kelly
et al., 2008; Le Sueur et al., 2010; Lobetti, 2012; Austin et al., 2013).
In this study endoscopy proved to be a valuable tool to conﬁrm that
oesophageal spirocercosis had already developed in dogs 140 days
after the ﬁrst experimental introduction of L3 larvae on Day -28.
Based on the life cycle, establishment of adults could be expected
as soon as 93 days after experimental infection. There is an appar-
ent discrepancy in number of nodules when comparing endoscopy
with necropsy results. Because of the elasticity of the oesophagus,
its mucosa is strongly folded and the folds tend to form small ridges
which could, during oesophagoscopy, be mistaken for either devel-
oping nodules, or nodules that were not yet completely resolved.
Peak egg production is reached between 140 and 205 days after
experimental infection (van der Merwe  et al., 2008). This was  con-
ﬁrmed in the current study, with no eggs present on Day 112.
Eggs were present in faecal samples from some negative control
group animals on Days 140 and from all control animals on Day
168, counted between 168 and 196 days after the ﬁrst experimen-
tal infection. The fact that no eggs were recovered from faecal
specimens from the NexGard Spectra® group could indicate poten-
tial suppression of egg laying. However, such a statement would
need to be conﬁrmed through additional research. The success of
detecting S. lupi eggs in faeces are variable and hence often consid-
ered unreliable as a diagnostic tool (Markovics and Medinski, 1996;
Mazaki-Tovi et al., 2002; Traversa et al., 2008). It is thus possible
that times of faecal collection did not correspond with the intermit-
tent S. lupi egg laying intervals (Lavy et al., 2003; Kok et al., 2011).
More likely is the fact that fewer worms  were present in the Nex-
Gard Spectra® treated group animals and hence also fewer eggs
could have been produced compared to negative control group.
Fewer eggs translate in increased difﬁculty of diagnosis. In this
regard more sensitive egg detection methods relating to both fae-
cal examination (Christie et al., 2011) and necropsy (De Lorenzi and
Furlanello, 2010) could be considered in future studies.
The fact that the number and size of aortic lesions did not differ
between groups, indicates that damage to the aorta and the poten-
tial for aortic rupture remained a signiﬁcant threat in both groups.
However, aorta wall lesions in the negative control group gener-
ally did present with visually apparent deeper pits and aneurysms.
In order to better quantify damage to the aorta and accurately
compare such damage between groups, more speciﬁc quantitative
assessment criteria may  be required. Earlier natural infection stud-
ies suggested that milbemycin oxime may  be effective against larval
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orta; B) Nodule in the oesophagus; C) Adult worms (n = 26 in total from both nodu
orms situated in or migrating from the aorta (Kelly et al., 2008; Kok
t al., 2010), but also indicated that pathological changes in the
orta will still occur with high levels of repeat infection (Kok et al.,
010). The milbemycin oxime formulation (Milbemax®: Novartis
nimal Health Inc.) employed by Kok et al. (2010) was  shown to
ave a mean residence time of approximately 5–6 days in fasted
ogs (Jung et al., 2002 cited in Kok et al., 2011).
The half-life for the two homologues (A3 and A4 forms) that
onstitute milbemycin-oxime in Nexgard Spectra® were shown
o be 1.6 ± 0.4 days and 3.3 ± 1.4 days, respectively (Committee
or Medicinal Products for Veterinary Use, 2014). This is similar
o what was cited by Kok et al. (2011) and could be expected,
s the plasma pharmacokinetic proﬁle of milbemycin was  shown
o be broadly similar when given alone or in combination with
foxolaner (Committee for Medicinal Products for Veterinary Use,
014). In addition absorption was shown to be quick with a Tmax of
ne to two hours. However, because of the short half-live relative
o the dosing interval of one month, it was shown that no accu-
ulation was present following monthly dosing (Committee for
edicinal Products for Veterinary Use, 2014). In the current studyhe ﬁrst treatment (Day 0) with NexGard Spectra® was  two  days
fter the third experimental infection occasion (Day -2) and 28 days
fter the ﬁrst inoculation on Day -28. Larvae inoculated on the latterfor animal 5CE 5EF (code K, negative control group). A) Lesions visible in the dorsal
covered from the oesophagus.
occasion thus had time to reach the aorta and cause damage prior
to NexGard Spectra® administration. Kok et al. (2011) also reported
on an experimental study with treatment every 28 days (four treat-
ments in total), commencing 28 days after experimental infection.
They concluded that milbemycin oxime does not reduce S. lupi
related damage within the aorta if administered after the larvae had
completed their ﬁrst stage of migration, as was  also the case in the
current study. As a result any potential prophylactic action against
larvae prior to onset of gastric, arterial and oesophageal migration
is unlikely under ﬁeld conditions with monthly treatments, con-
sidering the rapid onset of gastric migration at 24–48 h following
infection, combined with the fact that frequent yet intermittent
infections is likely to occur under natural conditions.
Kok et al. (2011) found no nodules and hence also no worms
in the oesophagus of animals treated with milbemycin oxime
28 days after infection, leading them to the conclusion that the
active demonstrated 100% efﬁcacy against pre-adult developmen-
tal stages of S. lupi and that the early use of the anthelmintic can
completely prevent the establishment of S. lupi within the oesoph-
agus. In the current study, even though nodules containing worms
were present in the oesophagus of 6 out of 8 animals treated with
NexGard Spectra®, worm numbers were low and calculated efﬁ-
cacy exceeded 90%, partially supporting the conclusion by (Kok
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t al., 2011) that early use of milbemycin-oxime can prevent the
stablishment of S. lupi within the oesophagus.
More than 5 worms were recovered from more than 6 animals
n the negative control group at necropsy on Day 168. Based on
xpert opinion and with consideration of the VICH GL19 guideline
Veterinary International Cooperation on Harmonization, 2001), it
s concluded that adequacy of infection was achieved. In addition
igniﬁcantly more worms were recovered from the negative con-
rol group and efﬁcacy based on both arithmetic and Geo means
xceeded 90%.
This study thus conﬁrms the therapeutic efﬁcacy of milbemycin-
xime in preventing the establishment of adult stages in the
esophagus, but not in preventing damage to the aorta once the
rst stage of larval migration has completed.
. Conclusion
Since all dogs in the control group were infected with 9 or more
dult S. lupi worms, adequacy of infection was  achieved. In the
reated group 6 of the dogs were infected with 5 or less S. lupi
orms.
Six consecutive monthly oral treatments with NexGard Spectra®
as 92.3% effective in the prevention of the establishment of adult S.
upi infections in experimentally infected dogs. In addition NexGardd for animal 5C4 87C (code G, NexGard Spectra® group). A) Lesions visible in the
gle nodule in the oesophagus.
Spectra® was 100% effective in reducing the number of eggs pro-
duced by adult S. lupi. However, milbemycin oxime did not reduce
S. lupi related damage within the aorta when administered after the
larvae had completed their ﬁrst stage of migration, conﬁrming the
ﬁndings by Kok et al. (2011).
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